Field of the Inventions
The present disclosure generally relates to intrasaccular medical devices, and more particularly, to a medical implant having a frame and a mesh component for occluding a target area of a patient's vasculature.
Description of the Related Art
Walls of the vasculature, particularly arterial walls, may develop areas of pathological dilatation called aneurysms. As is well known, aneurysms have thin, weak walls that are prone to rupturing. Aneurysms can be the result of the vessel wall being weakened by disease, injury or a congenital abnormality. Aneurysms could be found in different parts of the body with the most common being abdominal aortic aneurysms (AAA) and brain or cerebral aneurysms. When the weakened wall of an aneurysm ruptures, it can result in death.
Aneurysms are generally treated by excluding the weakened part of the vessel from the arterial circulation. For treating a cerebral aneurysm, such reinforcement is done in many ways including: (i) surgical clipping, where a metal clip is secured around the base of the aneurysm; (ii) packing the aneurysm with small, flexible wire coils (micro-coils) or braided ball devices; (iii) using embolic materials to “fill” or “pack” an aneurysm; (iv) using detachable balloons or coils to occlude the parent vessel that supplies the aneurysm; and (v) using stents to divert blood flow away from the aneurysm.
Additional features and advantages of the subject technology will be set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and embodiments hereof as well as the appended drawings.
Systems and procedures for treating aneurysms can include an implantable device that can be inserted into an aneurysm to facilitate a thrombotic, healing effect. The implantable device can have specific characteristics, including porosity, composition, material, shape, size, interconnectedness, inter-engagement, coating, etc. These characteristics can be selected in order to achieve a desired treatment or placement of the implantable device.
Implants or implantable devices for occluding a target area of a patient's vasculature, such as an aneurysm, can comprise a frame or frame component and one or more mesh components for mesh components that are coupled to the frame. The implantable device can be configured to provide an atraumatic, high surface area region that can promote endothelialization when the implantable device is implanted into a body lumen. The high surface area coverage can be created using a mesh component positioned along a given region of the frame. In some embodiments, a single mesh component can be coupled to the frame that has a generally constant porosity. However, the single mesh component can have a variable porosity. Further, multiple mesh components can be coupled to the frame that each have different porosities.
In some embodiments, the implantable device can have an average porosity that changes from a first end or region of the device to a second end or region of the device. Different regions of the device can define different porosities due to the presence of one or more mesh components in a given region or based on the porosity of the frame itself in a given region. Some embodiments therefore provide an implantable device that can have a first porosity in a distal region and a second porosity and a proximal region based on the presence of the mesh component in the proximal region of the device.
The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered embodiments (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent embodiments may be combined in any combination with each other or one or more other independent embodiments, to form an independent embodiment. The other embodiments can be presented in a similar manner. The following is a non-limiting summary of some embodiments presented herein:
Clause 1. An implant for occluding a target area of a patient's vasculature, comprising: a frame comprising a plurality of braided filaments that define a plurality of openings, the plurality of filaments and openings collectively defining a frame porosity, the frame comprising a distal region and a proximal region, the frame being expandable from a compressed configuration to an expanded configuration; and a mesh component coupled to the frame along at least the proximal region thereof, the mesh component comprising a plurality of filaments and a plurality of openings, the plurality of filaments and openings collectively defining a first porosity permitting blood flow therethrough, the first porosity being less than the frame porosity, such that blood flow into the implant is more restricted along the proximal region than along the distal region of the frame.
Clause 2. The implant of Clause 1, wherein the mesh component is a first mesh component, and the implant further comprises a second mesh component coupled to the frame along the proximal region.
Clause 3. The implant of Clause 2, wherein the second mesh component comprises a second porosity, different from the first porosity.
Clause 4. The implant of any of Clauses 2-3, wherein first and second mesh components overlie respective first and second openings in the frame, the first opening being adjacent to the second opening.
Clause 5. The implant of any of Clauses 2-4, wherein the second mesh component is positioned adjacent to the first mesh component.
Clause 6. The implant of any of Clauses 2-5, wherein an edge of the second mesh component borders an edge of the first mesh component.
Clause 7. The implant of any of Clauses 2-6, further comprising a third mesh component coupled to the frame along the proximal region.
Clause 8. The implant of Clause 7, wherein the third mesh component is positioned adjacent to the first mesh component.
Clause 9. The implant of any of Clauses 7-8, wherein the third mesh component comprises a third porosity, different from the first porosity.
Clause 10. The implant of any of Clauses 7-9, wherein the second mesh component comprises a second porosity, and the third mesh component comprises a third porosity, different from the second porosity.
Clause 11. The implant of Clause 10, wherein the first porosity is different from the second and third porosities.
Clause 12. The implant of any of Clauses 1-11, wherein the mesh component comprises a strip of material.
Clause 13. The implant of any of Clauses 1-12, wherein the frame comprises a globular shape.
Clause 14. The implant of Clause 13, wherein the frame comprises a spherical shape.
Clause 15. The implant of any of Clauses 13-14, wherein the frame comprises a rounded first portion and a substantially cylindrical second portion.
Clause 16. The implant of any of Clauses 1-15, wherein the mesh component is fixedly coupled to the frame at a plurality of coupling points.
Clause 17. The implant of Clause 16, wherein the mesh component is welded to the frame at the plurality of coupling points.
Clause 18. The implant of any of Clauses 1-17, wherein the mesh component comprises a braided material.
Clause 19. The implant of any of Clauses 1-18, wherein the mesh component is positioned along an exterior of the frame.
Clause 20. The implant of any of Clauses 1-19, wherein the frame and the mesh component are laminated together.
Clause 21. An implant for occluding a target area of a patient's vasculature, comprising a braided frame comprising filaments that intersect each other to define openings, the filaments and openings collectively defining a frame porosity, the frame being expandable from a compressed configuration to an expanded configuration, and a mesh component coupled to the frame, the mesh component comprising filaments and openings that collectively define a first porosity permitting blood flow therethrough, the first porosity being less than the frame porosity, for restricting blood flow into the implant.
Clause 22. The implant of Clause 21, wherein the mesh component is a first mesh component, and the implant further comprises a second mesh component coupled to the frame.
Clause 23. The implant of Clause 22, wherein the second mesh component comprises a second porosity, different from the first porosity.
Clause 24. The implant of any of Clauses 22-23, wherein first and second mesh components overlie respective first and second openings in the frame, the first opening being adjacent to the second opening.
Clause 25. The implant of any of Clauses 22-24, wherein the second mesh component is positioned adjacent to the first mesh component.
Clause 26. The implant of any of Clauses 22-25, wherein an edge of the second mesh component borders an edge of the first mesh component.
Clause 27. The implant of any of Clauses 22-26, further comprising a third mesh component coupled to the frame along the proximal region.
Clause 28. The implant of Clause 27, wherein the third mesh component is positioned adjacent to the first mesh component.
Clause 29. The implant of any of Clauses 27-28, wherein the third mesh component comprises a third porosity, different from the first porosity.
Clause 30. The implant of any of Clauses 27-29, wherein the second mesh component comprises a second porosity, and the third mesh component comprises a third porosity, different from the second porosity.
Clause 31. The implant of Clause 30, wherein the first porosity is different from the second and third porosities.
Clause 32. The implant of any of Clauses 21-31, wherein the mesh component surrounds substantially all of the frame.
Clause 33. The implant of any of Clauses 21-32, wherein the mesh component is disposed along an interior of the frame.
Clause 34. The implant of any of Clauses 21-33, wherein the mesh component is disposed along an exterior of the frame.
Clause 35. The implant of any of Clauses 21-34, wherein the mesh component is fixedly coupled to the frame at a plurality of coupling points.
Clause 36. The implant of any of Clauses 21-35, wherein the frame and the mesh component are welded together.
Clause 37. The implant of any of Clauses 21-36, wherein the pluralities of first and second filaments are interwoven to form a single layer.
Clause 38. The implant of any of Clauses 21-37, wherein the implant comprises a globular shape.
Clause 39. The implant of Clause 38, wherein the implant comprises a spherical shape.
Clause 40. The implant of any of Clauses 38-39, wherein the implant comprises a rounded first portion and a substantially cylindrical second portion.
Clause 41. A method of operating an implant assembly, comprising: closing an end a tubular braid to a substantially closed configuration using a tie, the tubular braid comprising filaments that intersect to define openings, the filaments and openings collectively defining a frame porosity; while holding the end substantially closed, inserting a form into an open end to position the braid around the form; setting a device frame shape based on the form provide an implant; and coupling a mesh component onto the implant, the mesh component comprising filaments and openings that collectively define a first porosity permitting blood flow therethrough, the first porosity being less than the frame porosity, for restricting blood flow into the implant.
Clause 42. The method of Clause 41, wherein the coupling comprises laminating the mesh component onto the tubular braid.
Clause 43. The method of any of Clauses 41-42, wherein the coupling comprises welding the mesh component to the tubular braid.
Clause 44. The method of any of Clauses 41-43, wherein the mesh component comprises a first mesh component, and the coupling comprises coupling a second mesh component to the implant adjacent to the first mesh component.
Clause 45. The method of Clause 44, wherein the coupling comprises coupling a third mesh component to the implant.
Clause 46. The method of any of Clauses 41-45, wherein the coupling comprises positioning the mesh component along an exterior of the implant.
Clause 47. The method of any of Clauses 41-46, wherein the closing comprises collapsing a midsection of a tubular braid to a substantially closed configuration using the tie and inverting a first tubular section of the tubular braid over the tie at the midsection to produce dual layers in the braid such that the braid has a tubular configuration with a closed end at the midsection and an open end opposite the midsection.
Clause 48. The method of any of Clauses 41-47, further comprising removing the tie from the braid.
Clause 49. The method of Clause 47, wherein the removing the tie comprises burning away the tie during heatsetting.
Clause 50. The method of any of Clauses 41-49, further comprising removing the form from the braid.
The method of any of Clauses 41-50, wherein the removing comprises removing the form in one piece.
Clause 52. An implant having any of the features of any of the previous Clauses.
Clause 53. A method of manufacturing any of the implants or assemblies of any of the previous Clauses.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology.
The accompanying drawings, which are included to provide further understanding of the subject technology and are incorporated in and constitute a part of this specification, illustrate aspects of the disclosure and together with the description serve to explain the principles of the subject technology.
In the following detailed description, numerous specific details are set forth to provide a full understanding of the subject technology. It should be understood that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and techniques have not been shown in detail so as not to obscure the subject technology.
Referring now to the figures,
As illustrated in
The mesh component 104 shown in
Referring still to
The mesh component 104 can be coupled to the implantable device 100 by a variety of mechanical, chemical, and thermal methods well known in medical device manufacture. Depending on the materials selected for implant manufacture, the mesh component 104 can be spot welded, partially melted or heated, or coupled using an adhesive or glue. Alternatively, the mesh component 104 can be coupled to the frame 102 by weaving, threading, or otherwise interconnecting the mesh component 104 with one or more filaments 106 of the frame 102. In some embodiments, the coupling between the mesh component 104 and the filaments 106 can require or utilize additional components or materials. Such embodiments can, for example, utilize sutures or ties to couple the mesh component 104 to filaments 106.
In some embodiments, the mesh component 104 can be laminated to the frame 102 by application of pressure and/or heat, adhesives, or other bonding methods, such as those described above. Further, in some embodiments, a lamination of multiple mesh layers with at least one frame layer can be achieved. As discussed herein, a variety of coatings and other materials can be applied to the structure of the implantable device 100, which can also function to maintain an engagement between the mesh component 104 and the frame 102.
In some embodiments, it is desirable to pretreat the one or more filaments 106 and/or at least a portion of the mesh component 104 to enhance the coupling process. For example, one or more of the filaments 106 (or at least a portion of the frame 102) and/or at least a portion of the mesh component 104 can be pretreated to modify a structural property, such as surface roughness, and/or to add a coating thereto. The surface roughness can be increased by passing a filament and/or a portion of the mesh component through a particulate or chemical bath or otherwise physically contacting a filament and/or the mesh component, e.g., as individual wires prior to being woven into the structure of the frame 102 or prior to being woven into the structure of the mesh component 104. Further, one or more of the filaments 106 (or at least a portion of the frame 102) and/or at least a portion of the mesh component 104 can be coated, e.g., as individual wires, prior to attempting to couple the frame 102 and the mesh component 104. For example, a filament and/or a portion of the mesh component can be coated with a urethane prior to attempting to couple the frame 102 and the mesh component 104. Thus, if one or both of a filament or the mesh component has a coating, heat can be applied during the coupling process to cause the coating (e.g., a urethane) to melt and couple the frame 102 and the mesh component 104 together.
In embodiments the implantable device 100 may vary in porosity gradually, as through a single mesh component comprised of varying pitch, or through the combination of several mesh components 104 coupled to the frame 102. When coupled to the frame 102 along at least the proximal region 132, as illustrated in
Additionally, an implantable device can comprise more than two regions, such as three, four, five, or more regions, as shown, for example, in
As it used herein, the term “porosity” can refer to the surface porosity of the implantable device. The surface porosity can be defined as the ratio of empty space (i.e., the surface area of the openings in the mesh component and/or frame) and the total surface area of a given region of the device. In order to calculate the porosity of the implantable device along a specific region of the frame covered by mesh component, the surface area of the openings may be found by first determining the total surface area of filaments in the specific region, accounting for all filaments in the specific region, and calculating a topographical or 2-D representation of total filament area, based on the dimensions (width or diameter and length) of filaments of the frame and/or the dimensions (width or diameter and length) of filaments of the mesh component. The total surface area of the frame and/or mesh component can then be subtracted from the total surface area of the given region in order to provide a resulting surface area of the openings in the given region.
In calculating the porosity of a given region or section of the device, a person of skill in the art can use images of a given device to guide or facilitate the calculation of the openings surface area and total surface area ratio. Such a calculation can rely on known information regarding the size and/or quantity of fibers or filaments in the frame and/or mesh component used in the implantable device.
For example, as shown in
As shown in
In light of potential variable porosity structures of frames formed from tubular braided materials, in which opposing ends of the braid are collapsed, thereby causing filaments of the braid to converge towards each other and create regions of decreased porosity, as discussed above with respect to “braid balls,” some embodiments can be configured such that one or more mesh components is coupled to the frame and defines a variable porosity that, when summed or combined with the porosity of the underlying or overlying section of the frame, defines a porosity that is substantially constant along one or more sections or substantially the entirety of the surface area of the implantable device. Accordingly, some embodiments can provide implantable devices having a braided material whose variable porosity is offset by a mesh component having a variable porosity such that the composite porosity of the frame and the mesh component at any given location in a section or anywhere along the surface of the implantable component defines a substantially constant porosity.
For example,
As shown in
The one or more mesh components can be coupled to the frame along an outer aspect or surface of the frame, such that the mesh component represents an outermost layer coupled to the frame, or along an inner aspect or interior of the frame, such that the frame generally encloses the mesh component within an inner volume of the frame or is coupled to the mesh component primarily along an interior-facing surface of the frame.
With particular reference to
The first and second mesh components 352, 354 can extend adjacent to each other along the frame 356. However, some embodiments can be provided in which different mesh components extend along the frame in different locations of the frame. Otherwise,
In accordance with some embodiments, methods are provided for forming devices having one or more of the features disclosed herein. The frame and the mesh component can be coupled to each other before or after the frame is formed into a globular component, such as a spherical component. For example,
In accordance with some embodiments, when the frame comprises a braided material (i.e., when the frame is formed using a tubular braid), one of the advantages provided by some embodiments includes the ability to use any of a variety of braid and/or wire configurations. For example, the tubular braid can be formed using as few as 4, 5, or 6 wires. A distinct advantage of some embodiments is a minimal frame with the minimal amount of braid mesh. Another advantage of some embodiments is the substantially reduced profile possible during advancement of the device compared to other devices that use 36, 72, 144, or more wires. Such a reduced profile enables some embodiments to be delivered through much lower-sized catheters, such as 6 Fr, 5 Fr, or 4 Fr. The number of wires can be determined by counting the number of wire ends at the end of the braided tube. In some embodiments having a lower number of wires, e.g., 12 or fewer wires, the primary function of the frame is to provide structural and expansion characteristics. Thus, in such embodiments, the mesh component can primarily provide a desired porosity profile for the implantable device.
In any of the embodiments disclosed herein, the mesh component can optionally comprise a polymer cover, layer, or coating that is applied to the frame after the frame is in a rounded or globular configuration, as shown in
In accordance with some embodiments, a method of manufacturing the implantable device can be performed as illustrated in
Thereafter, in
Other compression forms and methods for positioning the tubular member 430 can be used, such as those described in U.S. patent application Ser. No. 13/048,648, filed on Mar. 15, 2011, the entirety of which is incorporated herein by reference.
In implementing the methods for manufacturing implantable devices in accordance with some embodiments disclosed herein, the configuration, size, porosity profile, and number of mesh components can be varied or modified in order to achieve a final implantable device having desired porosity characteristics. Some of the porosity characteristics have been illustrated above with respect to
Delivery Methods
Furthermore, delivery systems and procedures can be implemented for delivering an implantable device comprising one or more implantable devices, as discussed herein. Further, a system and method are provided for delivery of an implantable device to an aneurysm and/or recapturing the device for removal or repositioning.
According to some embodiments, one or more of implantable devices can be released into a target aneurysm and, in some embodiments, specifically oriented relative to the aneurysm ostium or neck and/or one or more perforating vessels (e.g., perforating arteries or arterioles) adjacent to the aneurysm.
In some embodiments, the implantable device can be released into the target vasculature and mechanically expanded using a balloon or other device. For example, the implantable device can be balloon expanded to facilitate expansion of the frame of the device. This expansion force can ensure that a coated or composite device is able to expand sufficiently, as desired.
In use, an access catheter is advanced within the neurovasculature as is conventional in the art. A suitable microcatheter adaptable for navigation through the tortuous neurovascular space to access the treatment site is disclosed in commonly assigned U.S. Pat. No. 7,507,229, the entire contents of which are hereby incorporated herein.
In some embodiments, the implantable device can be repositioned within the aneurysm as the device is expanding. The repositioning of the device can allow a clinician to position a lower porosity section of the device adjacent to or away from the neck of the aneurysm. The repositioning of the device can also allow a clinician to position a higher average porosity section of the device adjacent to one or more perforating vessels (e.g., perforating arteries or arterials) adjacent to the aneurysm. The repositioning of the device can also allow a clinician to position a lower porosity portion of the device adjacent to a bifurcation. The repositioning of the device can also allow a clinician to position a higher average porosity portion of the device toward or in the fundus of the aneurysm.
For example, referring now to
Similarly,
Further, in accordance with some embodiments, the implantable device or a portion of the implantable device can be used in conjunction with other treatment modalities. For example, the implantable device can be delivered and subsequently packed with a liquid embolic The injection of a liquid embolic can increase the overall packing density within the implantable device. Additionally, coils can be introduced through an open end or pore of the implantable device.
In implementing a method for placing an implantable device within an aneurysm and injecting coils, expandable components, or other materials into the implantable device, the open end or widest interstices of the implantable device can be positioned at the neck of the aneurysm so as to facilitate insertion of the distal end of the catheter into the open end or between the filaments (i.e., into an interstice) of the implantable device. In embodiments having a braided material for the implantable device, the braid pattern can be properly aligned to facilitate entry of the materials into the implantable device. As in other embodiments disclosed herein, the implantable device can comprise a radiopaque material or component that facilitates visualization and enables the clinician to align the implantable device as needed within the aneurysm.
The composite effect of the coils, expandable components, and/or other materials inserted into the implantable device can provide the advantages and benefits discussed above with respect to various other implantable devices. As such, the clinician can determine and control various intrasaccular implant characteristics, including porosity, composition, material, shape, size, interconnectedness, inter-engagement, coating, etc.
According to some embodiments, systems or kits having an implantable device and at least one coil, expandable component, and/or other material can be provided.
Composite Porosity
In some embodiments, a composite structure of the implantable device can comprise two or three materials having different porosities. Further, the composite structure of the implantable device can comprise four, five, six, or more different materials having different porosities. Some embodiments of the implantable device can be configured to provide a specific porosity profile. The porosity profile can comprise a single, consistent average porosity across the surface of the entire implantable device, or multiple average porosity zones, portions, or regions having different average porosities that collectively form a composite implantable device.
For example, some embodiments can be configured to have a low average surface porosity. For purposes of illustration, high surface porosity is illustrated in the Figures using hexagonal patterns with larger-sized hexagons compared to hexagonal patterns with smaller-sized hexagons, which are used to illustrate medium and low porosity structures. Low surface porosity can provide higher resistance to blood flow therethrough, which can facilitate thrombogenesis. When such low porosity implantable devices are implanted into an aneurysm, such devices can tend to isolate the aneurysm from the parent vessel and minimize blood flow velocity within the aneurysm while supporting the aneurysm wall.
Conversely, as surface porosity increases, blood flow through the implantable device can increase, thereby tending to provide less support for thrombogenesis due to lower resistance to flow therethrough. Nevertheless, the realization of some embodiments disclosed herein is that high porosity structures can also support the aneurysm wall, beneficially aid in healing and thrombogenesis for select aneurysm morphologies, permit flow to other vessels (e.g., branch vessels, perforating arteries, or arterioles), and/or permit the introduction of other materials, such as a liquid embolic, etc.
The porosity of the implantable device may vary along any portion(s) thereof, including any combination of pore sizes of 1 micron or greater. Further, the pores or openings of the frame and mesh component(s) can range from about 1 μm to about 400 μm, from about 5 μm to about 300 μm, from about 8 μm to about 200 μm, from about 10 μm to about 150 μm, from about 15 μm to about 80 μm, or in some embodiments, from about 20 μm to about 50 μm. Further, at least a portion or section of the device can comprise an average porosity of between about 1 μm and about 150 μm. Further, at least a portion or section can comprise an average pore size of between about 100 μm and about 200 μm. Furthermore, at least a portion or section can comprise an average pore size of between about 200 μm and about 300 μm. When an implantable device is formed using multiple sections or portions, each section or portion can have an average porosity within any of the ranges discussed above. Furthermore, a pore size can be calculated using an “inscribed circle” calculation in which size of a given pore is represented by the diameter of the largest circle that fits into the given pore.
Further Embodiments
In accordance with some embodiments, at least a portion of the implantable device can comprise a coating or material for enhancing therapeutic, expansive, or imaging properties or characteristics of at least one or every implantable device.
In some embodiments, the implantable device can be coated with a biocompatible material to promote endothelialization or provide a therapeutic effect.
The coating may include thrombogenic coatings such as fibrin, fibrinogen or the like, anti-thrombogenic coatings such as heparin (and derivatives thereof), urukinase or t-PA, and endothelialization promoting coatings or facilitators such as, e.g., VEGF and RGD peptide, and/or combinations thereof. Drug eluting coatings and a drug eluting foam composite, such as anti-inflammatory or antibiotic, coatings are also envisioned. These drug eluting components may include nutrients, antibiotics, anti-inflammatory agents, antiplatelet agents, anesthetic agents such as lidocaine, and anti-proliferative agents, e.g., taxol derivatives such as paclitaxel. Hydrophilic, hygroscopic, and hydrophobic materials/agents are also envisioned.
Optionally, the implantable device can also comprise an expansion-limiting coating that slows expansion of the device from its natural rate of expansion to a slower rate of expansion such that in the process of expanding, the position of the device can be adjusted within the aneurysm or the device can be removed from the aneurysm, if necessary. Examples of polymers that can be used as expansion-limiting coatings can include hydrophobic polymers, organic non-polar polymers, PTFE, polyethylene, polyphenylene sulfide, oils, and other similar materials.
In embodiments, only specific segments of the implantable device may be embedded or coated with an agent to provide desired characteristics to the implantable device(s). For example, an implantable device can comprise a non-thrombogenic coating may be applied to a lower half of the implantable device to minimize clotting at this location. Such coatings may be desirable in aneurysms located at a bifurcation such that blood flow to branch arteries is permitted through the segment of the foam structure having the non-thrombogenic coating. The coated area may be a different color than the remaining portion of the implantable device to assist the surgeon in identifying this area.
Optionally, the coated area can also comprise radiopaque material to assist the surgeon in visualization and placement of the implantable device in a desired orientation relative to the aneurysm. The implantable device can have radiopacity characteristics either by adding radiopaque filler to the material (which in some embodiments comprises a foam material), such as bismuth, or attaching radiopaque markers. Alternatively, a radiopaque material can be coupled to the implantable device, such as by dipping, spraying, or otherwise mechanically, chemically, or thermally coupled, injected into, or blended into to the implantable device.
Further Aspects of Some Embodiments
The apparatus and methods discussed herein are not limited to the deployment and use of a medical device or stent within the vascular system but may include any number of further treatment applications. Other treatment sites may include areas or regions of the body including any hollow anatomical structures.
The foregoing description is provided to enable a person skilled in the art to practice the various configurations described herein. While the subject technology has been particularly described with reference to the various Figures and configurations, it should be understood that these are for illustration purposes only and should not be taken as limiting the scope of the subject technology.
There may be many other ways to implement the subject technology. Various functions and elements described herein may be partitioned differently from those shown without departing from the scope of the subject technology. Various modifications to these configurations will be readily apparent to those skilled in the art, and generic principles defined herein may be applied to other configurations. Thus, many changes and modifications may be made to the subject technology, by one having ordinary skill in the art, without departing from the scope of the subject technology.
It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.
Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.
The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments.
A reference to an element in the singular is not intended to mean “one and only one” unless specifically stated, but rather “one or more.” Pronouns in the masculine (e.g., his) include the feminine and neuter gender (e.g., her and its) and vice versa. The term “some” refers to one or more. Underlined and/or italicized headings and subheadings are used for convenience only, do not limit the subject technology, and are not referred to in connection with the interpretation of the description of the subject technology. All structural and functional equivalents to the elements of the various configurations described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and intended to be encompassed by the subject technology. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.
Although the detailed description contains many specifics, these should not be construed as limiting the scope of the subject technology but merely as illustrating different examples and aspects of the subject technology. It should be appreciated that the scope of the subject technology includes other embodiments not discussed in detail above. Various other modifications, changes and variations may be made in the arrangement, operation and details of the method and apparatus of the subject technology disclosed herein without departing from the scope of the present disclosure. Unless otherwise expressed, reference to an element in the singular is not intended to mean “one and only one” unless explicitly stated, but rather is meant to mean “one or more.” In addition, it is not necessary for a device or method to address every problem that is solvable (or possess every advantage that is achievable) by different embodiments of the disclosure in order to be encompassed within the scope of the disclosure. The use herein of “can” and derivatives thereof shall be understood in the sense of “possibly” or “optionally” as opposed to an affirmative capability.
Number | Name | Date | Kind |
---|---|---|---|
3108593 | Glassman | Oct 1963 | A |
4425908 | Simon | Jan 1984 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4655771 | Wallsten | Apr 1987 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4921484 | Hillstead | May 1990 | A |
4998539 | Delsanti | Mar 1991 | A |
5026377 | Burton et al. | Jun 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5104404 | Wolff | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5222971 | Willard et al. | Jun 1993 | A |
5250071 | Palermo | Oct 1993 | A |
5308356 | Blackshear, Jr. et al. | May 1994 | A |
5334210 | Gianturco | Aug 1994 | A |
5354295 | Guglielmi et al. | Oct 1994 | A |
5378239 | Termin et al. | Jan 1995 | A |
5405379 | Lane | Apr 1995 | A |
5425984 | Kennedy et al. | Jun 1995 | A |
5484444 | Braunschweiler et al. | Jan 1996 | A |
5499981 | Kordis | Mar 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5545208 | Wolff et al. | Aug 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5549635 | Solar | Aug 1996 | A |
5624461 | Mariant | Apr 1997 | A |
5634942 | Chevillon et al. | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5669931 | Kupiecki et al. | Sep 1997 | A |
5690671 | McGurk et al. | Nov 1997 | A |
5702419 | Berry et al. | Dec 1997 | A |
5713907 | Hogendijk et al. | Feb 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5728906 | Eguchi et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5741333 | Frid | Apr 1998 | A |
5749891 | Ken et al. | May 1998 | A |
5749919 | Blanc | May 1998 | A |
5749920 | Quiachon et al. | May 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5814062 | Sepetka et al. | Sep 1998 | A |
5830230 | Berryman et al. | Nov 1998 | A |
5846261 | Kotula et al. | Dec 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855578 | Guglielmi et al. | Jan 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5911731 | Pham et al. | Jun 1999 | A |
5916235 | Guglielmi | Jun 1999 | A |
5925060 | Forber | Jul 1999 | A |
5928228 | Kordis et al. | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5935362 | Petrick | Aug 1999 | A |
5941249 | Maynard | Aug 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5957948 | Mariant | Sep 1999 | A |
5976162 | Doan et al. | Nov 1999 | A |
5980554 | Lenker et al. | Nov 1999 | A |
6001092 | Mirigian et al. | Dec 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6033423 | Ken et al. | Mar 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6059813 | Vrba et al. | May 2000 | A |
6063070 | Eder | May 2000 | A |
6063104 | Villar et al. | May 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096034 | Kupiecki et al. | Aug 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099526 | Whayne et al. | Aug 2000 | A |
6106530 | Harada | Aug 2000 | A |
6110191 | Dehdashtian et al. | Aug 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6139564 | Teoh | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6168615 | Ken et al. | Jan 2001 | B1 |
6168618 | Frantzen | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6183495 | Lenker et al. | Feb 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6193708 | Ken et al. | Feb 2001 | B1 |
6217609 | Haverkost | Apr 2001 | B1 |
6221086 | Forber | Apr 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6280412 | Pederson, Jr. et al. | Aug 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6309367 | Boock | Oct 2001 | B1 |
6322576 | Wallace et al. | Nov 2001 | B1 |
6325815 | Kusleika | Dec 2001 | B1 |
6325820 | Khosravi et al. | Dec 2001 | B1 |
6331184 | Abrams | Dec 2001 | B1 |
6332576 | Colley et al. | Dec 2001 | B1 |
6342068 | Thompson | Jan 2002 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6346117 | Greenhalgh | Feb 2002 | B1 |
6350270 | Roue | Feb 2002 | B1 |
6361545 | Macoviak | Mar 2002 | B1 |
6361558 | Hieshima et al. | Mar 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6379372 | Dehdashtian et al. | Apr 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6443972 | Bosma et al. | Sep 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6454780 | Wallace | Sep 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6530934 | Jacobsen et al. | Mar 2003 | B1 |
6544278 | Vrba et al. | Apr 2003 | B1 |
6547804 | Porter et al. | Apr 2003 | B2 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6569179 | Teoh et al. | May 2003 | B2 |
6579302 | Duerig et al. | Jun 2003 | B2 |
6579303 | Amplatz | Jun 2003 | B2 |
6585748 | Jeffree | Jul 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589256 | Forber | Jul 2003 | B2 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592605 | Lenker et al. | Jul 2003 | B2 |
6599308 | Amplatz | Jul 2003 | B2 |
6602261 | Greene et al. | Aug 2003 | B2 |
6605101 | Schaefer et al. | Aug 2003 | B1 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6605111 | Bose et al. | Aug 2003 | B2 |
6607551 | Sullivan et al. | Aug 2003 | B1 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6635069 | Teoh et al. | Oct 2003 | B1 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6652556 | VanTassel et al. | Nov 2003 | B1 |
6666882 | Bose et al. | Dec 2003 | B1 |
6666883 | Seguin et al. | Dec 2003 | B1 |
6669717 | Marotta et al. | Dec 2003 | B2 |
6669721 | Bose et al. | Dec 2003 | B1 |
6676696 | Marotta et al. | Jan 2004 | B1 |
6682505 | Bates et al. | Jan 2004 | B2 |
6682546 | Amplatz | Jan 2004 | B2 |
6689150 | VanTassel et al. | Feb 2004 | B1 |
6689486 | Ho et al. | Feb 2004 | B2 |
6695876 | Marotta et al. | Feb 2004 | B1 |
6698877 | Urlaub et al. | Mar 2004 | B2 |
6699274 | Stinson | Mar 2004 | B2 |
6709465 | Mitchell et al. | Mar 2004 | B2 |
6712835 | Mazzocchi et al. | Mar 2004 | B2 |
6723112 | Ho et al. | Apr 2004 | B2 |
6723116 | Taheri | Apr 2004 | B2 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6746890 | Gupta et al. | Jun 2004 | B2 |
6780196 | Chin et al. | Aug 2004 | B2 |
6792979 | Konya et al. | Sep 2004 | B2 |
6797083 | Peterson | Sep 2004 | B2 |
6802851 | Jones et al. | Oct 2004 | B2 |
RE38653 | Igaki et al. | Nov 2004 | E |
6811560 | Jones et al. | Nov 2004 | B2 |
6855153 | Saadat | Feb 2005 | B2 |
6855154 | Abdel-Gawwad | Feb 2005 | B2 |
RE38711 | Igaki et al. | Mar 2005 | E |
6860893 | Wallace et al. | Mar 2005 | B2 |
6878384 | Cruise et al. | Apr 2005 | B2 |
6936055 | Ken et al. | Aug 2005 | B1 |
6949103 | Mazzocchi et al. | Sep 2005 | B2 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6979341 | Scribner et al. | Dec 2005 | B2 |
6989019 | Mazzocchi et al. | Jan 2006 | B2 |
6994092 | van der Burg et al. | Feb 2006 | B2 |
6994717 | Konya et al. | Feb 2006 | B2 |
7011671 | Welch | Mar 2006 | B2 |
7018401 | Hyodoh et al. | Mar 2006 | B1 |
7029487 | Greene, Jr. et al. | Apr 2006 | B2 |
7033375 | Mazzocchi et al. | Apr 2006 | B2 |
7048752 | Mazzocchi et al. | May 2006 | B2 |
7063679 | Maguire et al. | Jun 2006 | B2 |
7070607 | Murayama et al. | Jul 2006 | B2 |
7070609 | West | Jul 2006 | B2 |
7083632 | Avellanet et al. | Aug 2006 | B2 |
7128073 | van der Burg et al. | Oct 2006 | B1 |
7128736 | Abrams et al. | Oct 2006 | B1 |
7169177 | Obara | Jan 2007 | B2 |
7195636 | Avellanet et al. | Mar 2007 | B2 |
7211109 | Thompson | May 2007 | B2 |
7229461 | Chin et al. | Jun 2007 | B2 |
7232461 | Ramer | Jun 2007 | B2 |
7244267 | Huter et al. | Jul 2007 | B2 |
7261720 | Stevens et al. | Aug 2007 | B2 |
7303571 | Makower et al. | Dec 2007 | B2 |
7306622 | Jones et al. | Dec 2007 | B2 |
7331980 | Dubrul et al. | Feb 2008 | B2 |
7367985 | Mazzocchi et al. | May 2008 | B2 |
7367986 | Mazzocchi et al. | May 2008 | B2 |
7371250 | Mazzocchi et al. | May 2008 | B2 |
7393358 | Malewicz | Jul 2008 | B2 |
7404820 | Mazzocchi et al. | Jul 2008 | B2 |
7410482 | Murphy et al. | Aug 2008 | B2 |
7410492 | Mazzocchi et al. | Aug 2008 | B2 |
7413622 | Peterson | Aug 2008 | B2 |
7419503 | Pulnev et al. | Sep 2008 | B2 |
7442200 | Mazzocchi et al. | Oct 2008 | B2 |
7485088 | Murphy et al. | Feb 2009 | B2 |
7556635 | Mazzocchi et al. | Jul 2009 | B2 |
7566338 | Mazzocchi et al. | Jul 2009 | B2 |
7569066 | Gerberding et al. | Aug 2009 | B2 |
7572273 | Mazzocchi et al. | Aug 2009 | B2 |
7572288 | Cox | Aug 2009 | B2 |
7575590 | Watson | Aug 2009 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7601160 | Richter | Oct 2009 | B2 |
7608088 | Jones et al. | Oct 2009 | B2 |
7621928 | Thramann et al. | Nov 2009 | B2 |
7632296 | Malewicz | Dec 2009 | B2 |
7670355 | Mazzocchi et al. | Mar 2010 | B2 |
7670356 | Mazzocchi et al. | Mar 2010 | B2 |
7678130 | Mazzocchi et al. | Mar 2010 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7695488 | Berenstein et al. | Apr 2010 | B2 |
7699056 | Tran et al. | Apr 2010 | B2 |
7727189 | VanTassel et al. | Jun 2010 | B2 |
7744583 | Seifert et al. | Jun 2010 | B2 |
7744652 | Morsi | Jun 2010 | B2 |
7763011 | Ortiz et al. | Jul 2010 | B2 |
7828815 | Mazzocchi et al. | Nov 2010 | B2 |
7828816 | Mazzocchi et al. | Nov 2010 | B2 |
7906066 | Wilson et al. | Mar 2011 | B2 |
7922732 | Mazzocchi et al. | Apr 2011 | B2 |
7955343 | Makower et al. | Jun 2011 | B2 |
7972359 | Kreidler | Jul 2011 | B2 |
RE42625 | Guglielmi | Aug 2011 | E |
7993364 | Morsi | Aug 2011 | B2 |
RE42758 | Ken et al. | Sep 2011 | E |
8016869 | Nikolchev | Sep 2011 | B2 |
8016872 | Parker | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8062379 | Morsi | Nov 2011 | B2 |
8075585 | Lee et al. | Dec 2011 | B2 |
8142456 | Rosqueta et al. | Mar 2012 | B2 |
8202280 | Richter | Jun 2012 | B2 |
8221445 | van Tassel et al. | Jul 2012 | B2 |
8261648 | Marchand et al. | Sep 2012 | B1 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
8333783 | Braun et al. | Dec 2012 | B2 |
8425541 | Masters et al. | Apr 2013 | B2 |
8430012 | Marchand et al. | Apr 2013 | B1 |
8454681 | Holman et al. | Jun 2013 | B2 |
8470013 | Duggal et al. | Jun 2013 | B2 |
8715317 | Janardhan et al. | May 2014 | B1 |
8906057 | Connor et al. | Dec 2014 | B2 |
9179918 | Levy et al. | Nov 2015 | B2 |
9211202 | Strother et al. | Dec 2015 | B2 |
9486224 | Riina et al. | Nov 2016 | B2 |
9833309 | Levi et al. | Dec 2017 | B2 |
9844380 | Furey | Dec 2017 | B2 |
9907684 | Connor et al. | Mar 2018 | B2 |
9962146 | Hebert et al. | May 2018 | B2 |
10028745 | Morsi | Jul 2018 | B2 |
20010000797 | Mazzocchi | May 2001 | A1 |
20010001835 | Greene et al. | May 2001 | A1 |
20010007082 | Dusbabek et al. | Jul 2001 | A1 |
20010012949 | Forber | Aug 2001 | A1 |
20010031981 | Evans | Oct 2001 | A1 |
20010051822 | Stack et al. | Dec 2001 | A1 |
20020013599 | Limon et al. | Jan 2002 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020042628 | Chin et al. | Apr 2002 | A1 |
20020062091 | Jacobsen et al. | May 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020165572 | Saadat | Nov 2002 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20030004538 | Secrest et al. | Jan 2003 | A1 |
20030018294 | Cox | Jan 2003 | A1 |
20030028209 | Teoh et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030074049 | Hoganson | Apr 2003 | A1 |
20030114917 | Holloway | Jun 2003 | A1 |
20030171739 | Murphy et al. | Sep 2003 | A1 |
20030171770 | Kusleika et al. | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030195553 | Wallace et al. | Oct 2003 | A1 |
20030199913 | Dubrul et al. | Oct 2003 | A1 |
20030199919 | Palmer et al. | Oct 2003 | A1 |
20040015224 | Armstrong et al. | Jan 2004 | A1 |
20040034386 | Fulton et al. | Feb 2004 | A1 |
20040044391 | Porter | Mar 2004 | A1 |
20040044396 | Clerc | Mar 2004 | A1 |
20040098027 | Teoh | May 2004 | A1 |
20040098030 | Makower et al. | May 2004 | A1 |
20040106945 | Thramann et al. | Jun 2004 | A1 |
20040106977 | Sullivan et al. | Jun 2004 | A1 |
20040111112 | Hoffmann | Jun 2004 | A1 |
20040122467 | VanTassel et al. | Jun 2004 | A1 |
20040122468 | Yodfat et al. | Jun 2004 | A1 |
20040143239 | Zhou et al. | Jul 2004 | A1 |
20040143286 | Johnson et al. | Jul 2004 | A1 |
20040153119 | Kusleika et al. | Aug 2004 | A1 |
20040162606 | Thompson | Aug 2004 | A1 |
20040172056 | Guterman et al. | Sep 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040181253 | Sepetka et al. | Sep 2004 | A1 |
20040186562 | Cox | Sep 2004 | A1 |
20040193206 | Gerberding et al. | Sep 2004 | A1 |
20040215229 | Coyle | Oct 2004 | A1 |
20040215332 | Frid | Oct 2004 | A1 |
20040249408 | Murphy et al. | Dec 2004 | A1 |
20040267346 | Shelso | Dec 2004 | A1 |
20050010281 | Yodfat et al. | Jan 2005 | A1 |
20050021077 | Chin et al. | Jan 2005 | A1 |
20050033408 | Jones et al. | Feb 2005 | A1 |
20050033409 | Burke et al. | Feb 2005 | A1 |
20050043750 | Scott, III | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050060017 | Fischell et al. | Mar 2005 | A1 |
20050096728 | Ramer | May 2005 | A1 |
20050096732 | Marotta et al. | May 2005 | A1 |
20050107823 | Leone et al. | May 2005 | A1 |
20050131443 | Abdel-Gawwad | Jun 2005 | A1 |
20050222605 | Greenhalgh et al. | Oct 2005 | A1 |
20050228434 | Amplatz et al. | Oct 2005 | A1 |
20050267511 | Marks et al. | Dec 2005 | A1 |
20050267568 | Berez et al. | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050288763 | Andreas et al. | Dec 2005 | A1 |
20060052816 | Bates et al. | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060074475 | Gumm | Apr 2006 | A1 |
20060106421 | Teoh | May 2006 | A1 |
20060116713 | Sepetka et al. | Jun 2006 | A1 |
20060116714 | Sepetka et al. | Jun 2006 | A1 |
20060155323 | Porter et al. | Jul 2006 | A1 |
20060167494 | Suddaby | Jul 2006 | A1 |
20060190070 | Dieck et al. | Aug 2006 | A1 |
20060190076 | Taheri | Aug 2006 | A1 |
20060200221 | Malewicz | Sep 2006 | A1 |
20060200234 | Hines | Sep 2006 | A1 |
20060206199 | Churchwell et al. | Sep 2006 | A1 |
20060206200 | Garcia et al. | Sep 2006 | A1 |
20060217799 | Mailander et al. | Sep 2006 | A1 |
20060229700 | Acosta et al. | Oct 2006 | A1 |
20060235464 | Avellanet et al. | Oct 2006 | A1 |
20060235501 | Igaki | Oct 2006 | A1 |
20060241690 | Amplatz et al. | Oct 2006 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20060264905 | Eskridge et al. | Nov 2006 | A1 |
20060264907 | Eskridge et al. | Nov 2006 | A1 |
20060271149 | Berez et al. | Nov 2006 | A1 |
20060271153 | Garcia et al. | Nov 2006 | A1 |
20060276827 | Mitelberg et al. | Dec 2006 | A1 |
20060282152 | Beyerlein et al. | Dec 2006 | A1 |
20060292206 | Kim et al. | Dec 2006 | A1 |
20060293744 | Peckham et al. | Dec 2006 | A1 |
20070005125 | Berenstein et al. | Jan 2007 | A1 |
20070016243 | Ramaiah et al. | Jan 2007 | A1 |
20070021816 | Rudin | Jan 2007 | A1 |
20070050017 | Sims et al. | Mar 2007 | A1 |
20070066993 | Kreidler | Mar 2007 | A1 |
20070088387 | Eskridge et al. | Apr 2007 | A1 |
20070093889 | Wu et al. | Apr 2007 | A1 |
20070100415 | Licata et al. | May 2007 | A1 |
20070100426 | Rudakov et al. | May 2007 | A1 |
20070106311 | Wallace et al. | May 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070150045 | Ferrera | Jun 2007 | A1 |
20070162104 | Frid | Jul 2007 | A1 |
20070173928 | Morsi | Jul 2007 | A1 |
20070175536 | Monetti et al. | Aug 2007 | A1 |
20070191884 | Eskridge et al. | Aug 2007 | A1 |
20070191924 | Rudakov | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070203567 | Levy | Aug 2007 | A1 |
20070219619 | Dieck et al. | Sep 2007 | A1 |
20070221230 | Thompson et al. | Sep 2007 | A1 |
20070225760 | Moszner et al. | Sep 2007 | A1 |
20070225794 | Thramann et al. | Sep 2007 | A1 |
20070233224 | Leynov et al. | Oct 2007 | A1 |
20070233244 | Lopez et al. | Oct 2007 | A1 |
20070239261 | Bose et al. | Oct 2007 | A1 |
20070265656 | Amplatz et al. | Nov 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070288083 | Hines | Dec 2007 | A1 |
20070293935 | Olsen et al. | Dec 2007 | A1 |
20080009934 | Schneider et al. | Jan 2008 | A1 |
20080021535 | Leopold et al. | Jan 2008 | A1 |
20080039933 | Yodfat et al. | Feb 2008 | A1 |
20080045996 | Makower et al. | Feb 2008 | A1 |
20080045997 | Balgobin et al. | Feb 2008 | A1 |
20080051705 | Von Oepen et al. | Feb 2008 | A1 |
20080058856 | Ramaiah et al. | Mar 2008 | A1 |
20080065141 | Holman et al. | Mar 2008 | A1 |
20080065145 | Carpenter | Mar 2008 | A1 |
20080097495 | Feller, III et al. | Apr 2008 | A1 |
20080109063 | Hancock et al. | May 2008 | A1 |
20080114391 | Dieck et al. | May 2008 | A1 |
20080114436 | Dieck et al. | May 2008 | A1 |
20080114439 | Ramaiah et al. | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080125806 | Mazzocchi et al. | May 2008 | A1 |
20080125848 | Kusleika et al. | May 2008 | A1 |
20080132989 | Snow et al. | Jun 2008 | A1 |
20080140177 | Hines | Jun 2008 | A1 |
20080154286 | Abbott et al. | Jun 2008 | A1 |
20080195139 | Donald et al. | Aug 2008 | A1 |
20080219533 | Grigorescu | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080243226 | Fernandez et al. | Oct 2008 | A1 |
20080249562 | Cahill | Oct 2008 | A1 |
20080262598 | Elmaleh | Oct 2008 | A1 |
20080281350 | Sepetka et al. | Nov 2008 | A1 |
20080319533 | Lehe | Dec 2008 | A1 |
20090025820 | Adams | Jan 2009 | A1 |
20090069806 | De La Mora Levy et al. | Mar 2009 | A1 |
20090082803 | Adams et al. | Mar 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090112251 | Qian et al. | Apr 2009 | A1 |
20090118811 | Moloney | May 2009 | A1 |
20090125094 | Rust | May 2009 | A1 |
20090143849 | Ozawa et al. | Jun 2009 | A1 |
20090143851 | Paul, Jr. | Jun 2009 | A1 |
20090198315 | Boudjemline | Aug 2009 | A1 |
20090204145 | Matthews | Aug 2009 | A1 |
20090210047 | Amplatz et al. | Aug 2009 | A1 |
20090216307 | Kaufmann et al. | Aug 2009 | A1 |
20090228029 | Lee | Sep 2009 | A1 |
20090228093 | Taylor et al. | Sep 2009 | A1 |
20090259202 | Leeflang et al. | Oct 2009 | A1 |
20090264914 | Riina et al. | Oct 2009 | A1 |
20090275974 | Marchand et al. | Nov 2009 | A1 |
20090287291 | Becking et al. | Nov 2009 | A1 |
20090287294 | Rosqueta et al. | Nov 2009 | A1 |
20090287297 | Cox | Nov 2009 | A1 |
20090292348 | Berez et al. | Nov 2009 | A1 |
20090318941 | Sepetka et al. | Dec 2009 | A1 |
20090318948 | Linder et al. | Dec 2009 | A1 |
20100004726 | Hancock et al. | Jan 2010 | A1 |
20100004761 | Flanders et al. | Jan 2010 | A1 |
20100023048 | Mach | Jan 2010 | A1 |
20100023105 | Levy et al. | Jan 2010 | A1 |
20100030220 | Truckai et al. | Feb 2010 | A1 |
20100036390 | Gumm | Feb 2010 | A1 |
20100042133 | Ramzipoor et al. | Feb 2010 | A1 |
20100069948 | Veznedaroglu et al. | Mar 2010 | A1 |
20100087908 | Hilaire et al. | Apr 2010 | A1 |
20100094335 | Gerberding et al. | Apr 2010 | A1 |
20100106178 | Obermiller et al. | Apr 2010 | A1 |
20100131002 | Connor et al. | May 2010 | A1 |
20100144895 | Porter | Jun 2010 | A1 |
20100152767 | Greenhalgh et al. | Jun 2010 | A1 |
20100185271 | Zhang | Jul 2010 | A1 |
20100222802 | Gillespie, Jr. et al. | Sep 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100256667 | Ashby et al. | Oct 2010 | A1 |
20100268260 | Riina et al. | Oct 2010 | A1 |
20100274276 | Chow et al. | Oct 2010 | A1 |
20100312270 | McGuckin, Jr. et al. | Dec 2010 | A1 |
20100331948 | Turovskiy et al. | Dec 2010 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110054519 | Neuss | Mar 2011 | A1 |
20110082493 | Samson et al. | Apr 2011 | A1 |
20110106234 | Grandt | May 2011 | A1 |
20110130826 | Cragg | Jun 2011 | A1 |
20110137405 | Wilson et al. | Jun 2011 | A1 |
20110144669 | Becking et al. | Jun 2011 | A1 |
20110152993 | Marchand et al. | Jun 2011 | A1 |
20110184452 | Huynh et al. | Jul 2011 | A1 |
20110184453 | Levy et al. | Jul 2011 | A1 |
20110196415 | Ujiie et al. | Aug 2011 | A1 |
20110202085 | Loganathan et al. | Aug 2011 | A1 |
20110208227 | Becking | Aug 2011 | A1 |
20110245862 | Dieck et al. | Oct 2011 | A1 |
20110265943 | Rosqueta et al. | Nov 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110313447 | Strauss et al. | Dec 2011 | A1 |
20110319926 | Becking | Dec 2011 | A1 |
20120041470 | Shrivastava et al. | Feb 2012 | A1 |
20120065720 | Strauss et al. | Mar 2012 | A1 |
20120101561 | Porter | Apr 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120143317 | Cam et al. | Jun 2012 | A1 |
20120165803 | Bencini et al. | Jun 2012 | A1 |
20120165919 | Cox et al. | Jun 2012 | A1 |
20120197283 | Marchand et al. | Aug 2012 | A1 |
20120226343 | Vo et al. | Sep 2012 | A1 |
20120245674 | Molaei et al. | Sep 2012 | A1 |
20120245675 | Molaei et al. | Sep 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120316598 | Becking et al. | Dec 2012 | A1 |
20120316632 | Gao | Dec 2012 | A1 |
20120330341 | Becking et al. | Dec 2012 | A1 |
20120330347 | Becking et al. | Dec 2012 | A1 |
20130018451 | Grabowski et al. | Jan 2013 | A1 |
20130066357 | Aboytes et al. | Mar 2013 | A1 |
20130066360 | Becking et al. | Mar 2013 | A1 |
20130085522 | Becking et al. | Apr 2013 | A1 |
20130092013 | Thompson et al. | Apr 2013 | A1 |
20130123830 | Becking et al. | May 2013 | A1 |
20130204351 | Cox et al. | Aug 2013 | A1 |
20130211495 | Halden et al. | Aug 2013 | A1 |
20130233160 | Marchand et al. | Sep 2013 | A1 |
20130239790 | Thompson et al. | Sep 2013 | A1 |
20130245667 | Marchand et al. | Sep 2013 | A1 |
20130245670 | Fan | Sep 2013 | A1 |
20130268053 | Molaei et al. | Oct 2013 | A1 |
20130274862 | Cox et al. | Oct 2013 | A1 |
20130274863 | Cox et al. | Oct 2013 | A1 |
20130274866 | Cox et al. | Oct 2013 | A1 |
20130274868 | Cox et al. | Oct 2013 | A1 |
20130304179 | Bialas et al. | Nov 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140005713 | Bowman | Jan 2014 | A1 |
20140012307 | Franano et al. | Jan 2014 | A1 |
20140058420 | Hannes et al. | Feb 2014 | A1 |
20140074151 | Tischler et al. | Mar 2014 | A1 |
20140128905 | Molaei | May 2014 | A1 |
20140135810 | Divino | May 2014 | A1 |
20140135817 | Tischler | May 2014 | A1 |
20140172001 | Becking et al. | Jun 2014 | A1 |
20140200648 | Newell et al. | Jul 2014 | A1 |
20140243882 | Ma | Aug 2014 | A1 |
20140277361 | Farhat et al. | Sep 2014 | A1 |
20140277400 | Wainwright et al. | Sep 2014 | A1 |
20140316012 | Freyman et al. | Oct 2014 | A1 |
20140358178 | Hewitt | Dec 2014 | A1 |
20140371734 | Truckai | Dec 2014 | A1 |
20150133989 | Lubock | May 2015 | A1 |
20150157331 | Levy et al. | Jun 2015 | A1 |
20150173770 | Warner et al. | Jun 2015 | A1 |
20150209050 | Aboytes et al. | Jul 2015 | A1 |
20150216684 | Enzmann et al. | Aug 2015 | A1 |
20150250628 | Monstadt et al. | Sep 2015 | A1 |
20150313737 | Tippett et al. | Nov 2015 | A1 |
20150327843 | Garrison | Nov 2015 | A1 |
20160066921 | Seifert et al. | Mar 2016 | A1 |
20160135984 | Rudakov et al. | May 2016 | A1 |
20160206320 | Connor | Jul 2016 | A1 |
20160206321 | Connor | Jul 2016 | A1 |
20170150971 | Hines | Jun 2017 | A1 |
20170156903 | Shobayashi | Jun 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170266023 | Thomas | Sep 2017 | A1 |
20170340333 | Badruddin et al. | Nov 2017 | A1 |
20170367708 | Mayer et al. | Dec 2017 | A1 |
20180049859 | Stoppenhagen et al. | Feb 2018 | A1 |
20180125686 | Lu | May 2018 | A1 |
20180140305 | Connor | May 2018 | A1 |
20180161185 | Kresslein et al. | Jun 2018 | A1 |
20180193025 | Walzman | Jul 2018 | A1 |
20180193026 | Yang et al. | Jul 2018 | A1 |
20180206852 | Moeller | Jul 2018 | A1 |
20190053811 | Garza et al. | Feb 2019 | A1 |
Number | Date | Country |
---|---|---|
2607529 | Apr 2008 | CA |
101472537 | Jul 2009 | CN |
1283434 | Nov 1968 | DE |
102008028308 | Apr 2009 | DE |
102010050569 | May 2012 | DE |
102011011510 | Aug 2012 | DE |
743047 | Nov 1996 | EP |
775470 | May 1997 | EP |
855170 | Jul 1998 | EP |
1621148 | Feb 2006 | EP |
1637176 | Mar 2006 | EP |
1752112 | Feb 2007 | EP |
1942972 | Jul 2008 | EP |
1872742 | May 2009 | EP |
2279023 | Feb 2011 | EP |
2363075 | Sep 2011 | EP |
2496299 | Sep 2012 | EP |
2675402 | Dec 2013 | EP |
2777640 | Sep 2014 | EP |
2556210 | Apr 1988 | FR |
2890306 | Mar 2007 | FR |
11-506686 | Jun 1999 | JP |
2003520103 | Jul 2003 | JP |
2003-524434 | Aug 2003 | JP |
2004-049585 | Feb 2004 | JP |
2005-522266 | Jul 2005 | JP |
2006-506201 | Feb 2006 | JP |
2008513140 | May 2008 | JP |
2008-541832 | Nov 2008 | JP |
4673987 | Apr 2011 | JP |
2011518023 | Jun 2011 | JP |
2014533743 | Dec 2014 | JP |
2015091416 | May 2015 | JP |
20150084959 | Jul 2015 | KR |
WO-8800813 | Feb 1988 | WO |
WO-9601591 | Jan 1996 | WO |
WO-9726939 | Jul 1997 | WO |
WO-9903404 | Jan 1999 | WO |
WO-9905977 | Feb 1999 | WO |
WO-9908607 | Feb 1999 | WO |
WO-9908743 | Feb 1999 | WO |
WO-9940873 | Aug 1999 | WO |
WO-9962432 | Dec 1999 | WO |
WO-0057815 | Oct 2000 | WO |
0174255 | Oct 2001 | WO |
WO-01093782 | Dec 2001 | WO |
WO-02000139 | Jan 2002 | WO |
WO-02071977 | Sep 2002 | WO |
WO-03037191 | May 2003 | WO |
2004085590 | Oct 2004 | WO |
WO-2005117718 | Dec 2005 | WO |
2006034140 | Mar 2006 | WO |
WO-2006026744 | Mar 2006 | WO |
WO-2006034166 | Mar 2006 | WO |
WO-2006052322 | May 2006 | WO |
WO-2006091891 | Aug 2006 | WO |
WO-2006119422 | Nov 2006 | WO |
WO-2007047851 | Apr 2007 | WO |
WO-2007076480 | Jul 2007 | WO |
WO-2007095031 | Aug 2007 | WO |
WO-2007121405 | Oct 2007 | WO |
WO-2008022327 | Feb 2008 | WO |
WO-20080109228 | Sep 2008 | WO |
WO-2008157507 | Dec 2008 | WO |
WO-2008151204 | Dec 2008 | WO |
2009008868 | Jan 2009 | WO |
WO-2009076515 | Jun 2009 | WO |
2009132045 | Oct 2009 | WO |
WO-2009132045 | Oct 2009 | WO |
WO-2009134337 | Nov 2009 | WO |
WO-2009135166 | Nov 2009 | WO |
WO-2010028314 | Mar 2010 | WO |
WO-2010030991 | Mar 2010 | WO |
WO-2010147808 | Dec 2010 | WO |
WO-2011057002 | May 2011 | WO |
WO-2011057277 | May 2011 | WO |
2011066962 | Jun 2011 | WO |
WO-2011130081 | Oct 2011 | WO |
WO-2011153304 | Dec 2011 | WO |
WO-2012068175 | May 2012 | WO |
WO-2012112749 | Aug 2012 | WO |
WO-2012166804 | Dec 2012 | WO |
2014085590 | Jun 2014 | WO |
2017074411 | May 2017 | WO |
2018051187 | Mar 2018 | WO |
Entry |
---|
European Search Report dated Mar. 9, 2017; European Patent Application No. 16189394.6; 8 pages. |
Hill, et al., “Initial Results of the AMPLATZER Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing,” US Cardiology 2004. |
Ronnen, “AMPLATZER Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007. |
Thorell, et al., “Y-configured Dual Intracranial Stent-assisted Coil Embolization for the Treatment of Wide-necked Basilar Tip Aneurysms”, Neurosurgery, May 2005, vol. 56, Issue 5, pp. 1035-1040. |
U.S. Appl. No. 14/791,941, filed Jul. 6, 2015. |
U.S. Appl. No. 14/862,522, filed Sep. 23, 2015. |
U.S. Appl. No. 14/932,330, filed Nov. 4, 2015. |
Number | Date | Country | |
---|---|---|---|
20170079662 A1 | Mar 2017 | US |